✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Bristol-Myers Squibb Co

Common Name
Bristol-Myers Squibb
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
32,500
Ticker
BMY
Exchange
NEW YORK STOCK EXCHANGE, INC.
Description
Bristol-Myers Squibb Company is a global biopharmaceutical firm founded in 1887 that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines worldwide. Its po...

Bristol-Myers Squibb's GHG Emissions Data Preview

In 2024, Bristol-Myers Squibb completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Bristol-Myers Squibb has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Total Scope 2
Market-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Location-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Total Scope 3
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Limited Data Preview
You are viewing a limited preview of Bristol-Myers Squibb’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2019, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=BMY&reporting_period=2024"

Verified Sources Behind Bristol-Myers Squibb’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Bristol-Myers Squibb’s data sources below and access millions more through our Disclosure Search.

a. Bristol-Myers Squibb's ESG Report 2024
b. Bristol-Myers Squibb's ESG Report 2021

Insights into Bristol-Myers Squibb's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Bristol-Myers Squibb amounted to 356,562 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Bristol-Myers Squibb decreased by 2.94%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Bristol-Myers Squibb's Scope 1 Emissions Over Time

201920202021202220232024055 k110 k165 k220 ktCO2e-7%-5%+11%-2%-1%
  • Total Scope 1
  • Year-over-Year Change

What are Bristol-Myers Squibb's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Bristol-Myers Squibb were 206,726 metric tons of CO₂ equivalent (tCO₂e).a

Has Bristol-Myers Squibb reduced its Scope 1 emissions over time?

Since 2019, Bristol-Myers Squibb's Scope 1 emissions have decreased by 5.25%, reflecting a declining long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2023), Bristol-Myers Squibb's Scope 1 emissions remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its operational footprint.a

What are Bristol-Myers Squibb's Scope 2 emissions?

In 2024, Bristol-Myers Squibb reported Scope 2 greenhouse gas (GHG) emissions of 104,649 tCO₂e using the market-based method and 149,836 tCO₂e using the location-based method.a

Has Bristol-Myers Squibb reduced its Scope 2 emissions over time?

Compared to the previous year (2023), Bristol-Myers Squibb's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Bristol-Myers Squibb use for Scope 2 reporting?

In 2024, Bristol-Myers Squibb reported its Scope 2 emissions using the market-based method and using the location-based method.a

Bristol-Myers Squibb's Scope 2 Emissions Over Time

201920202021202220232024045 k90 k135 k180 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Bristol-Myers Squibb's Value Chain Emissions

In 2024, Bristol-Myers Squibb reported 1,700,746 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Bristol-Myers Squibb includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Bristol-Myers Squibb's Scope 3 Emissions Over Time

2019202020212022202320240500 k1 M1.5 M2 MtCO2e-83%+10575%-6%-1%-3%
  • Total Scope 3
  • Year-over-Year Change

What are Bristol-Myers Squibb's Scope 3 emissions?

In 2024, Bristol-Myers Squibb reported total Scope 3 emissions of 1,700,746 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 93.44% of these emissions originated from upstream activities such as purchased goods and capital goods, while 6.56% came from downstream activities like product use, distribution, and end-of-life treatment.a

Has Bristol-Myers Squibb reduced its Scope 3 emissions over time?

Since 2019, Bristol-Myers Squibb's Scope 3 emissions have increased by 1,546.41%, reflecting a rising long-term trend in Scope 3 emissions over time.ab

Compared to the previous year (2023), Bristol-Myers Squibb's Scope 3 emissions remained relatively stable, indicating that Bristol-Myers Squibb's emissions have plateaued with no significant change in its value chain footprint.a

What categories of Scope 3 emissions does Bristol-Myers Squibb disclose?

In 2024, Bristol-Myers Squibb reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This reflects a high level of granularity and transparency in the company's emissions reporting.

What are the main sources of Bristol-Myers Squibb's Scope 3 emissions?

In 2024, the largest contributors to Bristol-Myers Squibb's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 1,218,474 tCO₂e (71.64%)
  • Upstream Transportation and Distribution (Cat. 4): 149,090 tCO₂e (8.77%)
  • Investments (Cat. 15): 108,127 tCO₂e (6.36%)

Bristol-Myers Squibb's Scope 3 Emissions by Categories

Purchased Goods andServices (Cat. 1)(71.6%)Investments(Cat. 15)(6.4%)UpstreamTransportation andDistribution(Cat. 4)(8.8%)

Insights into Bristol-Myers Squibb’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Bristol-Myers Squibb reported Scope 1 greenhouse gas (GHG) emissions of 206,726 tCO₂e and total revenues of USD 48,300 millions. This translates into an emissions intensity of 4.28 tCO₂e per millions USD.a

Bristol-Myers Squibb's Scope 1 Emissions Intensity Compared to Peers

21002,000100,0002,000,000Scope 1 Emissions (tCO2e)1001,00010,000100,0001,000,000Revenues (Millions of USD)CCCCCencoraYear: 2024Scope 1: 135,087 tCO2eRevenue: $M 293,987Scope 1 Intensity: 0.46 tCO2e/$MMolina HealthcareYear: 2024Scope 1: 6,890 tCO2eRevenue: $M 40,646Scope 1 Intensity: 0.17 tCO2e/$MIQVIA HoldingsYear: 2023Scope 1: 8,221 tCO2eRevenue: $M 14,983Scope 1 Intensity: 0.55 tCO2e/$MCigna GroupYear: 2024Scope 1: 22,212 tCO2eRevenue: $M 244,356Scope 1 Intensity: 0.09 tCO2e/$MAbbott LaboratoriesYear: 2024Scope 1: 502,000 tCO2eRevenue: $M 41,950Scope 1 Intensity: 11.97 tCO2e/$MEli Lilly and CoYear: 2024Scope 1: 192,000 tCO2eRevenue: $M 45,043Scope 1 Intensity: 4.26 tCO2e/$MJohnson & JohnsonYear: 2024Scope 1: 314,690 tCO2eRevenue: $M 88,820Scope 1 Intensity: 3.54 tCO2e/$MHCA HealthcareYear: 2022Scope 1: 755 tCO2eRevenue: $M 60,400Scope 1 Intensity: 0.01 tCO2e/$MGilead SciencesYear: 2024Scope 1: 53,856 tCO2eRevenue: $M 28,754Scope 1 Intensity: 1.87 tCO2e/$MBiogenYear: 2024Scope 1: 56,611 tCO2eRevenue: $M 9,676Scope 1 Intensity: 5.85 tCO2e/$MPfizerYear: 2024Scope 1: 613,218 tCO2eRevenue: $M 63,627Scope 1 Intensity: 9.64 tCO2e/$MAmgenYear: 2024Scope 1: 147,000 tCO2eRevenue: $M 33,424Scope 1 Intensity: 4.40 tCO2e/$MOrganon & CoYear: 2024Scope 1: 34,200 tCO2eRevenue: $M 6,403Scope 1 Intensity: 5.34 tCO2e/$MAbbVieYear: 2024Scope 1: 300,072 tCO2eRevenue: $M 56,334Scope 1 Intensity: 5.33 tCO2e/$MMerck & Co IncYear: 2024Scope 1: 721,200 tCO2eRevenue: $M 64,168Scope 1 Intensity: 11.24 tCO2e/$MHumana IncYear: 2024Scope 1: 37,480 tCO2eRevenue: $M 117,751Scope 1 Intensity: 0.32 tCO2e/$MDexcomYear: 2024Scope 1: 8,328 tCO2eRevenue: $M 4,033Scope 1 Intensity: 2.07 tCO2e/$MCCCatalyst PharmaceuticalsYear: 2024Scope 1: 4 tCO2eRevenue: $M 493Scope 1 Intensity: 0.01 tCO2e/$MBoston ScientificYear: 2024Scope 1: 87,567 tCO2eRevenue: $M 16,747Scope 1 Intensity: 5.23 tCO2e/$MQuidelOrthoYear: 2023Scope 1: 22,544 tCO2eRevenue: $M 2,998Scope 1 Intensity: 7.52 tCO2e/$MElevance HealthYear: 2024Scope 1: 14,390 tCO2eRevenue: $M 176,781Scope 1 Intensity: 0.08 tCO2e/$MOmnicellYear: 2023Scope 1: 414 tCO2eRevenue: $M 1,147Scope 1 Intensity: 0.36 tCO2e/$MEnvista HoldingsYear: 2024Scope 1: 3,000 tCO2eRevenue: $M 2,511Scope 1 Intensity: 1.19 tCO2e/$MIntuitive SurgicalYear: 2024Scope 1: 8,105 tCO2eRevenue: $M 8,352Scope 1 Intensity: 0.97 tCO2e/$MBristol-Myers SquibbYear: 2024Scope 1: 206,726 tCO2eRevenue: $M 48,300Scope 1 Intensity: 4.28 tCO2e/$M

How does Bristol-Myers Squibb's GHG emissions intensity compare to its peers?

In 2024, Bristol-Myers Squibb reported a Scope 1 emissions intensity of 4.28 tCO₂e per millions USD. Compared to the peer group median of 1.97, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does Bristol-Myers Squibb rank on GHG emissions intensity within its industry?

In 2024, Bristol-Myers Squibb ranked 16 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Bristol-Myers Squibb is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Bristol-Myers Squibb's Total Carbon Footprint

In 2024, Bristol-Myers Squibb reported a total carbon footprint of 2,057,308 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.88% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a

The largest contributor to Bristol-Myers Squibb's total carbon footprint was Scope 3 emissions, accounting for 82.67% of the company's total carbon footprint, followed by Scope 1 emissions at 10.05%.a

Want Full Access to Bristol-Myers Squibb's GHG Emissions Dataset?
Start 30-Day Free Trial